Literature DB >> 25266188

Try235Phe homozygous mutation of the steroid 5-a reductase type 2 (SRD5A2) gene in a Turkish patient.

Mesut Parlak1, Erdem Durmaz, Semin Gursoy, Iffet Bircan, Sema Akcurin.   

Abstract

Steroid 5-a reductase type 2 isoenzyme (SRD5A2) deficiency is a male-limited autosomal recessive disorder that results in decreased conversion of testosterone to dihydrotestosterone with various de.gree of incomplete virilization in affected 46, XY infants. No clear genotype-phenotype relationship has been reported till date; moreover, the same mutation can result in considerable heterogeneity in clinical manifestations. Of 6 documented cases with Try235Phe homozygous mutation of the SRD5A2 gene, 3 patients had predominantly female external genitalia whereas the other 3 had predominantly male phenotype. We report Try235Phe homozygous mutation of the SRD5A2 gene in a Turkish patient who was initially assigned as a girl because of the predominantly female appearance of the external genitalia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25266188      PMCID: PMC6074591          DOI: 10.5144/0256-4947.2014.254

Source DB:  PubMed          Journal:  Ann Saudi Med        ISSN: 0256-4947            Impact factor:   1.526


Steroid 5-a reductase (5aR) type 2 isoenzyme deficiency is a male-limited autosomal recessive disorder causing 46, XY disorders of sex differentiation (DSD). 5aR type 2 enzyme converts testosterone (T) into the more biologically active form of dihydrotestosterone (DHT), which is necessary for the development of the external genitalia, urethra, and prostate in the male fetus. 5aR type 2 gene (SRD5A2) mutations decreased the synthesis of DHT, a key hormone of virilization at the male external genitalia. Various degree of incomplete virilization may be seen in the same homozygotic mutation.1–3 In this paper we report Try235Phe homozygous mutation of the SRD5A2 gene in a Turkish patient with predominantly female appearance of the external genitalia.

CASE

The patient was admitted to the pediatric endocrine department for the evaluation of DSD at the age of 6 days. In the prenatal period, the chromosomal study revealed a karyotype of 46, XY because of abnormal triple test. The patient weighed 2400 g at 38 weeks of gestation, with the normal delivery of a 36-year-old woman. The family history revealed a first-degree relationship between healthy parents, and the patient was the second child in the family. On clinical examination, the infant showed female phenotype, extremely hypoplastic penis (stretched length 1.5 cm) with a single phallic urethral opening, and palpable right testis in the labio-scrotum (Figure 1).
Figure 1

External genitalia of the patient with micropenis and hypospadias.

Pelvic ultrasonography showed no evidence of any mullerian structures. Genitography revealed a urogenital sinus without any vaginal pouch (Figure 2). Laboratory findings included normal serum electrolytes, 28.8 ng/mL 17-hydroxyprogesterone (17-OHP), and 1.19 ng/mL T. The karyotype was 46, XY. Human chorionic gonadotropin (hCG) test was performed at the age of 2 months. The basal plasma T value was 1.46 ng/mL, while T was 5.9 ng/mL and DHT was 0.21 ng/mL after hCG stimulation. A serum T/DHT ratio of 28.1 under hCG stimulation provided evidence for the diagnosis of 5aR deficiency. The SRD5A2 gene analysis revealed Try235Phe homozygous mutation in exon 5. The 17-OHP level decreased to 0.27 ng/mL at the follow-up period.
Figure 2

Normal genitography of the patient.

The patient’s sex was reared as male because of the parents’ insistent demand. Transdermal 25% DHT gel was administered for 4 months, resulting in an increase in penile legth to 3.5 cm (Picture 3).

Genetic analysis

Genomic DNA was extracted from the peripheral blood leukocytes of the patient using standard procedures. The entire SRD5A2 coding region (exons 1–5) was screened for mutations. Polymerase chain reaction (PCR) was performed to amplify all the exons and the exon–intron boundaries of SRD5A2 with the primers reported before. PCR settings, amplicons length, and annealing temperatures for PCR and sequencing analysis were reported elsewhere.4 After an initial round of PCR amplification, PCR products were visualized by agarose gel electrophoresis to check the quality of PCR products. Subsequently, PCR fragments were purified and subjected to cycle sequence reactions using BigDye Terminators (DNA sequencing kit, Applied Biosystems, Foster City, California, USA). The sequence fragments were precipitated and analyzed using an automated sequencer (ABI3130). Try235Phe (c.A704T) mutation was described with homozygous in the exon 5 SRD5A2 gene (Figure 4).
Figure 4

Electropherogram of segment of SRD5A2 pointing the homozygous c.A704T mutation.

DISCUSSION

To date, more than 50 SRD5A2 gene mutations have been identified. No clear genotype-phenotype relationship has been reported till date; moreover, the same mutation can result in considerable heterogeneity in clinical manifestations. Six documented cases exist with Try235Phe homozygous mutation of the SRD5A2 gene; 3 patients had predominantly female external genitalia whereas the other 3 had predominantly male phenotype (Table 1). Caucasian patient,1 Egyptian newborn,2 and Italian patient3 were predominantly female phenotypes, which were reared as female. Interestingly, the same homozygous mutation was also found in the Israeli patient with micropenis and hypospadias (Mazen et al, unpublished data, 2003); the two Italian patients of whom one presented only with perineoscrotal hypospadias and undescended testes (Nicoletti et al, 2005) and the other presented with micropenis, perineoscrotal hypospadias, and bilateral cryptorchidism (Baldinotti et al, 2008) were reared as male.1,3,5,6 Try235Phe homozygous mutation was previously known, but it was first reported in a turkish patient. 7 The deficiency of 5aR type 2 phenotype shows variation from male to female phenotype with hypospadias or only microphallus. This can thus be explained that some factors related to androgen receptor signal transduction, fetal effects of T or steroid 5-a reductase type 1 isoenzyme, or exposure to environmental chemicals may affect clinical expression of the disorder.
Table 1

Main clinical, hormonal, and molecular data of patients having 5αR type 2 deficiency with Try235Phe homozygous mutation.

AgePhenotypeSex of reraringMutationGeographical origin

Wigley et al,199431 yFemaleFemaleY235F in exon 5Caucasian, French
Mazen et al, 20039 moFemaleFemaleY235F in exon 5Egyptian
Mazen et al, 2003Micropenis, hypospadias in personal dataMaleY235F in exon 5Jewish Israeli
Nicoletti et al, 20053 yMild clitoromegaly, blind ending vaginal pouch, testes palpable in the labio-scrotumFemaleY235FItalian
Nicoletti et al, 20058 yPerineo-scrotal hypospadias, testes present in the scrotumMaleY235FItalian
Baldinotti et al, 20081 yMicropenis, hypospadias and bilateral cryptorchidismMaleTry235Phe in exon 5Italian (Sicily)
In conclusion, this was, to the best of our knowledge, the fourth case of predominantly female phenotype due to 5-a reductase type 2 defiency and the first case of Try235Phe homozygous mutation published in Turkish patients, which responded positive to the DHT gel treatment.
  6 in total

1.  Mutation analysis of five candidate genes in Chinese patients with hypospadias.

Authors:  Yanping Wang; Qiang Li; Jiajie Xu; Qingjie Liu; Weiqiu Wang; Yi Lin; Fen Ma; Taiji Chen; Senkai Li; Yan Shen
Journal:  Eur J Hum Genet       Date:  2004-09       Impact factor: 4.246

2.  SRD5A2 gene analysis in an Italian population of under-masculinized 46,XY subjects.

Authors:  Annalisa Nicoletti; Lilia Baldazzi; Antonio Balsamo; Lorella Barp; Piero Pirazzoli; Monia Gennari; Giorgio Radetti; Emanuele Cacciari; Alessandro Cicognani
Journal:  Clin Endocrinol (Oxf)       Date:  2005-10       Impact factor: 3.478

3.  Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation.

Authors:  Inas Mazen; Yehia Z Gad; Mona Hafez; Charles Sultan; Serge Lumbroso
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

4.  5 alpha steroid reductase deficiency in Turkey.

Authors:  Pelin Bilir Adiyaman; Gonul Ocal; Ergun Cetinkaya; Nejat Akar; Ali Uysal; Turker Duman; Olcay Evliyaoğlu; Zehra Aycan; Serge Lumbroso; Charles Sultan; Merih Berberoğlu
Journal:  Pediatr Endocrinol Rev       Date:  2006-08

5.  Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme.

Authors:  W C Wigley; J S Prihoda; I Mowszowicz; B B Mendonca; M I New; J D Wilson; D W Russell
Journal:  Biochemistry       Date:  1994-02-08       Impact factor: 3.162

6.  Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.

Authors:  F Baldinotti; S Majore; A Fogli; G Marrocco; P Ghirri; M Vuerich; S Tumini; B Boscherini; M Vetri; S Scommegna; R Rinaldi; P Simi; P Grammatico
Journal:  J Androl       Date:  2007-07-03
  6 in total
  2 in total

Review 1.  Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.

Authors:  Rafael Loch Batista; Berenice Bilharinho Mendonca
Journal:  Appl Clin Genet       Date:  2020-04-14

2.  Novel Genomic Variants, Atypical Phenotypes and Evidence of a Digenic/Oligogenic Contribution to Disorders/Differences of Sex Development in a Large North African Cohort.

Authors:  Housna Zidoune; Asmahane Ladjouze; Djalila Chellat-Rezgoune; Asma Boukri; Scheher Aman Dib; Nassim Nouri; Meryem Tebibel; Karima Sifi; Noureddine Abadi; Dalila Satta; Yasmina Benelmadani; Joelle Bignon-Topalovic; Maeva El-Zaiat-Munsch; Anu Bashamboo; Ken McElreavey
Journal:  Front Genet       Date:  2022-08-30       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.